tbuckley/cabot-search huggingface dataset:
436TiP DYNASTY-Breast02: A phase III trial of BNT323/DB-1303 vs investigator's choice chemotherapy in HER2-low, hormone receptor positive, metastatic breast cancer
Authors: J. O'Shaughnessy, J. Cortés, P. Schmid, B. Xu, Z. Shao, L. Teixeira, M.A.N. Sendur, D. Sabanathan, S-B. Kim, M.A. Colleoni, M. Wenger, J.H. Lee, V. Gu, Y. Qiu, S. Liu, H. Fang, R. Shi, Z. Zhu, E.P. Hamilton
Journal: Annals of Oncology (2024)
435TiP Molecular imaging of programmed death ligand 1 (PD-L1) expression with [89Zr]Zr-atezolizumab positron emission tomography/computed tomography (PET/CT) in patients with metastatic triple negative breast cancer (mTNBC): The MIMIR-study
Authors: R. Altena, A. Tzortzakakis, A. Blomgren, E. Jussing, S. Ekman, T. Tran, R. Axelsson, J. Bergh
Journal: Annals of Oncology (2024)
379P Safety and efficacy of trastuzumab deruxtecan and concomitant radiation therapy in patients with metastatic breast cancer: A multicentre international retrospective cohort study
Authors: L. Visani, I. Ratosa, B.K. Linderholm, D. Ribnikar, J. Scialino, N. Bertini, I. Bonaparte, D. Stefanovski, N. Dobnikar, M. Sojar, C. Mattioli, M. Valzano, V. Salvestrini, C. Becherini, A. Morandi, L. Livi, I. Meattini
Journal: Annals of Oncology (2024)
347MO The safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC)
Authors: Q. Ouyang, X. Wang, C. Tian, X. Shao, J. Huang, Z-H. Chen, Y. wang, T. Sun, T. Yi, X. Yu, Z.M. Wang, B. Li, Y. Xia
Journal: Annals of Oncology (2024)
974P Surufatinib combined with anti-PD-1/PD-L1 antibody in the second-line or monotherapy in third-line treatment of advanced hepatocellular carcinoma: A single-arm, open-label, multi-center phase II study
Authors: F. Zhou, L. Yang, J. Peng, H. Xu, H. Wu, Y. Wang, X. Long, Q. Gao, X. Shi, J. Gong, J. Hu
Journal: Annals of Oncology (2024)
967P Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients (P) progressed to atezolizumab plus bevacizumab (AB)
Authors: M. Persano, M. Rimini, T. Tada, G. Suda, S. Shimose, M. Kudo, C. Yoo, J. Cheon, F. Finkelmeier, H.Y. Lim, J. Presa, F. Rossari, E. Amadeo, F. Vitiello, S. Camera, S. Foti, L. Mascia, M. Scartozzi, S. Cascinu, A. Casadei Gardini
Journal: Annals of Oncology (2024)
1025P Fully intravenous delivery regimen of oncolytic adenovirus coding for TNFa and IL-2 (TILT-123) in patients with advanced solid cancers
Authors: S.A. Pakola, K. Jalkanen, T.V. Alanko, J.H.A. Clubb, D.C.A. Quixabeira, E. Jirovec, T. Kudling, V. Arias, R. Korpisaari, M. Jaakkola, J.T. Kononen, J. Sormunen, T. Pellinen, L. Haybout, C. Kistler, S. Sorsa, R. Havunen, J.M. Santos, V. Cervera-Carrascon, A. Hemminki
Journal: Annals of Oncology (2024)
852MO REWRITE–GORTEC 2018-02: Radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck
Authors: J. Castelli, X. sun, E. Neveu, T.V. Nguyen, Y. Tao, L. Martin, U. Schick, C. Sire, T. Leroy, N. Vulquin, B. Calderon, J. Thariat, S. Guihard, X. Liem, O. Arsene, L. Sinigaglia, B. Campillo-Gimenez, J. Bourhis
Journal: Annals of Oncology (2024)
390P SARELIFE: An Italian, multicentric real-world study of sacituzumab govitecan (SG) in pretreated metastatic triple-negative breast cancer (mTNBC)
Authors: M.S. Cona, L. Ruggieri, S.A.A. Artale, G. Catania, G. D'Auria, E. Gallerani, F. Villa, A. Gambaro, A. Chirco, M. Giordano, M. Pistelli, F. Verderame, A. Bramati, S.C. Stani, P. Vici, I. Meattini, B. Tagliaferri, B. Tedesco, O. Amato, N.M. La Verde
Journal: Annals of Oncology (2024)
366P Exploring the benefit of combining paclitaxel with capivasertib treatment in PI3K/AKT/PTEN-altered and non-altered TNBC preclinical models
Authors: C.A. Eberlein, L. Vasiliauskaite, J. Kerr, C. Blaker, S. Williamson, L. Hopcroft, S. Ros, J. Moss, E. De Bruin, C. Rooney, B. Willis, S. Dunn, S. Barry
Journal: Annals of Oncology (2024)
502O Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: Preliminary results of FFCD 1703 POCHI trial
Authors: D. Tougeron, J-F. Emile, A. Bodere, E. Barbier, J. Bez, L.M. Dourthe, H. Perrier, S. Corbinais, V. Le Brun-Ly, K. Bideau, B. Chibaudel, F. Khemissa Akouz, J. Hartwig, M. Laly, A. Lievre, C. Toullec, N. Lomenie, P. Laurent-Puig, C. Lepage, J. Taieb
Journal: Annals of Oncology (2024)
970P Comparing clinical outcomes between PD-1 and PD-L1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresectable hepatocellular carcinoma: A single-center, real-world study
Authors: Y. Pan, Z. Yuan, D. Hu, L. Xu, M. Chen, Y. Zhang, Z. Zhou
Journal: Annals of Oncology (2024)
373P Quality-of-life outcomes in patients with HER2-positive, locally advanced or metastatic breast cancer treated with eribulin mesylate in combination with trastuzumab and pertuzumab in the phase III JBCRG-M06/EMERALD study
Authors: N. Masuda, S. Saji, T. Iwatani, T. Takano, K. Koizumi, Y. Sagara, Y. Naito, M. Tsuneizumi, A. Yoshimura, M. Takahashi, J. Tsurutani, M. Kitada, H. Tada, T. Higuchi, Y. Kojima, T. Kadoya, H. Hasegawa, Y. Uchida, S. Morita, T. Yamashita
Journal: Annals of Oncology (2024)
450MO Characterization of tumor-infiltrating lymphocytes and tumor-associated macrophages within the tumor microenvironment of primary tumors and matched brain metastases
Authors: M. Kleinberger, D. Cifci, C. Paiato, E. Tomasich, M. Mair, A. Steindl, Z. Carrero, L. Berchtold, J. Hainfellner, L. Müllauer, G. Heller, M. Preusser, J.N. Kather, A.S. Berghoff
Journal: Annals of Oncology (2024)
807MO High efficacy and safety of interleukin-6-knockdown CD19-targeted CAR-T cells in relapsed/refractory B-ALL patients
Authors: L. Yu, L. Kang, S. Xue, X. Tang, X. Lou, C. Qian, W. Gong, M. Xu, H. Zhou, Z. Yao, W. Wang, M. Li, N. Xu, Z. Yu, S. Chen, H. Qiu, H. Dai, Y. Xu, D. Wu
Journal: Annals of Oncology (2024)
873P Nivolumab (NIVO) in the first-line (1L) or second-line (2L) and later (2L+) settings in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Updated results from the German non-interventional study (NIS), HANNA
Authors: A. Dietz, D.A. Hahn, C. Langer, B. Kubuschok, U. Bockmühl, H. Mueller-Huesmann, G. Klautke, B. Reuter, J. von der Grün, D. Beutner, J. Büntzel, C-J. Busch, B.F. Tamaskovics, J. Riera Knorrenschild, M.K. Welslau, T.C. Gauler, D. Waldenberger, E. Von der heyde
Journal: Annals of Oncology (2024)
328P Real-world evidence (RWE) of effectiveness and safety of TCHP regimen: INSIGHT-HER2BC trial interim results
Authors: D. Meretukov, K.S. Grechukhina, D. Stroyakovskiy, A. Danilova, I. Alekseenko, G. Mishurovsky, E. Kharitonova, L. Zhukova
Journal: Annals of Oncology (2024)
982P HILL: The efficacy and safety of hepatic arterial infusion chemotherapy with FOLFOX regimen combine lenvatinib and durvalumab in unresectable hepatocellular carcinoma: A prospective, phase II, single-armed, clinical trial
Authors: S. Li, L. Lu, Q. Wang, R. Zhao, J. Mei, J-B. Li, L. Zheng, W. Wei, R. Guo
Journal: Annals of Oncology (2024)
813MO Phase I trial of a personalized multi-peptide vaccine combined with the TLR1/2 ligand XS15 under Bruton-Tyrosine-Kinase inhibitor (BTKi) treatment in chronic lymphocytic leukemia (CLL) patients
Authors: C. Hackenbruch, J.S. Heitmann, S. Jung, Y. Maringer, M. Wacker, A. Nelde, M. Marconato, L. Zieschang, C. Kammer, M.T. Özbek, M. Richter, M. Denk, H.R. Salih, J.S. Walz
Journal: Annals of Oncology (2024)
359P Overall survival of palbociclib (PAL) + endocrine therapy (ET) in Japanese patients with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the 1st line (1L) or 2nd line (2L) setting: A multicenter observational study
Authors: T. Nakayama, S.E. Nagai, M. Hattori, T. Yoshinami, H. Masuda, T. Okamura, K-I. Watanabe, M. Tsuneizumi, D. Takabatake, M. Harao, H. Yasojima, C. Oshiro, M. Iwase, M. Yamaguchi, T. Sangai, S. Sasada, T. Ishida, M. Futamura, N. Kosaka, N. Masuda
Journal: Annals of Oncology (2024)
998MO Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study
Authors: O. Klein, B. Gao, H. Chan, M. Michael, R. Zielinski, J. So, S.J. Harris, D. Kee, I.M. Collins, W-S. Lam, M. Lyle, C.R. Underhill, M. Brown, R.A. Harrup, S.F. Wong, J.B. Palmer, D. Thomas, K. Wilkie, J. Cebon, M.S. Carlino
Journal: Annals of Oncology (2024)
800MO First report of BCL-2 inhibitor TQB3909 in pts with relapsed or refractory non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML): Data from a phase I study
Authors: J. Qi, J. Li, W. Xu, X. Zhao, Q. Yin, Y. Li, F. Xu, H. Huang, J. Li, W. Qian, Q. Zhao, J. Wang
Journal: Annals of Oncology (2024)
579P Intratumoral fusobacterium as prognostic factor in early stage colorectal cancer: Results of the FUSOMAP study
Authors: P.G. Nuciforo, F. Moratalla Navarro, I. Baraibar Argota, L. Alonso, G. serna, J. Vidal Barrull, L. Aguilera Castro, N. Mulet Margalef, A. Fernandez Montes, M. Cuatrecasas, I. Gardeazabal Gonzalez, E. Gonzalez, P. García Alfonso, S. Rosello Keranen, R. Comas, N. Bayo Puxan, R. FASANI, M. Obon, M.E. Elez Fernandez, V. Moreno Aguado
Journal: Annals of Oncology (2024)
882P Quitting smoking after diagnosis of head and neck cancer is associated with reduced risk of mortality: A multicentric prospective cohort study
Authors: M. Sheikh, S. Nemati, T. Dudding, M. Vilensky, M. Figari, L.M.R.B. Arantes, P. Rodriguez, M.P. Curado, L.P. Kowalski, J.C. de Oliveira, T. Waterboer, L.F. Ribeiro Pinto, F.L. Dias, S.C. Soares Lima, M. Cuello, S. Zeidler, M. Pring, A.C. de Carvalho Peters, S.P. Perdomo, S. Virani
Journal: Annals of Oncology (2024)
812MO Initial results of the multicenter phase II trial of a novel hypofractionated low-dose radiotherapy for indolent non-Hodgkin lymphoma
Authors: X-Y. Wang, L-R. Gao, L. Wang, X. Zhang, K. Chen, X. Feng, R. Zheng, Y-X. Li, S. Qi
Journal: Annals of Oncology (2024)
991O First-in-human (FIH) phase I data of HST-1011, an oral CBL-B inhibitor, in patients with advanced solid tumors
Authors: R.E. Sanborn, M.R. Patel, J. Rodon, K.Z. Thein, C. Friedman, D. Levitz, I. Ngirailemesang, A. Goodman, P. Agarwal, E. Friedman, H. Danaee, K. Robell, S. Jaeger, H. Sun, E. Debanne, J. Dunn, E. Wright, T. Reilly, J.J. Luke, A. Redig
Journal: Annals of Oncology (2024)
561P Liquid biopsy tracking of immunotherapy-induced T cell dynamics in MSS colorectal and endometrial tumors
Authors: H. Heyn, J.L. Melero, G. Deuner, I. Baraibar Argota, M. Grzelak, G. Caratu, C. Garcia Duran, J.F. Grau Béjar, D.G. Illescas, L. Fariñas Madrid, P. Nieto, S. Morabito, A. Rotem, P. Casbas-Hernandez, A. Gros, J. Tabernero, A. Oaknin, J.N. Sachica, N. Borcherding, M.E. Elez Fernandez
Journal: Annals of Oncology (2024)
350MO Omission of chemotherapy and addition of the CDK4/6 inhibitor ribociclib in HER2-positive and hormone-receptor positive metastatic breast cancer – Second interim efficacy analysis of the randomized phase III DETECT V trial
Authors: W. Janni, T.N. Fehm, V. Mueller, A.M.B. de Gregorio, T. Decker, A.D. Hartkopf, M. Just, J. Sagasser, M. Schmidt, P. Wimberger, T. Engler, M. Banys- Paluchowski, P.A. Fasching, B. Rack, A. Schneeweiss, J-U. Blohmer, J. Huober, K. Pantel, T.W.P. Friedl, F. Schochter
Journal: Annals of Oncology (2024)
865P Adjuvant toripalimab for locally advanced head and neck squamous cell carcinoma patients who achieved pathological complete response after neoadjuvant immunochemotherapy and surgery: A single-arm, phase II trial
Authors: S. Chen, S. Yan, W. Hu, Q. Lin, J. Zhou, W. Chen, X. Liu, Z. Guo, X. Zhang, C. Yang, X. Gao, M. Li, X. Li, S. Zhang, Y. Zhang, Q. Zhang, A. Yang, M. Song
Journal: Annals of Oncology (2024)
827P Comparison of efficacy and safety between glofitamab and real-world regimens among Chinese patients with 3L+ relapsed/refractory diffuse large B-cell lymphoma: An external control study
Authors: K. Zhou, H. Wu, X. Zhao, X. Tan, X. Yan, H. Liu, L. Su, Y. Lan, J. Xu, X. Zhou, Y. Shuang, H. Zhang
Journal: Annals of Oncology (2024)
988O A phase I/II trial (LOKON003) evaluating tumor microenvironment (TME) gene engineering using a viral vector combined with atezolizumab in advanced malignant melanoma
Authors: O. Hamid, V. Rydén, I. Mehmi, D. Wang, M. Patel, J. Krause, L.C. Sandin, H. Grauers Wiktorin, T. Lövgren, E. Eriksson, J. Leja Jarblad, A. Loskog, G.J. Ullenhag
Journal: Annals of Oncology (2024)
581P mRNA profiling as a biomarker of prognosis and response to first-line treatment in metastatic colorectal cancer: Discovery and validation of a gene expression signature in three randomized trials
Authors: M.M. Germani, V. Heinemann, F. Pietrantonio, L. Fischer von W., I-K. Na, B. Hoppe, A. Jarosch, S. Lonardi, F. Morano, E. Medico, M. Karthaus, S. Fruehauf, U. Graeven, T. Decker, F. Kaiser, S. Stintzing, A. Stahler, D.P. Modest
Journal: Annals of Oncology (2024)
1000MO A phase I/II, open-label study of the novel checkpoint IGSF8 inhibitor GV20-0251 in patients with advanced solid tumors
Authors: K. Wentzel, J. Peguero, S. Kummar, P. Lorusso, J.M. Mehnert, A.I. Spira, A. Naing, O. Hamid, I. Mehmi, K. Benhadji, L. Alland, X. Hu, H. Xiao, X. Bao, J. Chen, Y. Gong, X.S. Liu
Journal: Annals of Oncology (2024)
811MO An exploratory study to assess the safety, immunogenicity, and preliminary anti-tumor activity of the EBV mRNA vaccine (WGc-043 injection) in patients with NK/T cell lymphoma
Authors: X. Peng, J. Ji, M. Jing, W. Zhang, H. Huang, Y. Chen, X. Li, H. Zheng, J. Chen, Y. Wei, X. Song
Journal: Annals of Oncology (2024)
856P Safety of neoadjuvant PARP inhibitor and immunotherapy in locally advanced HPV-negative head and neck squamous cell carcinoma (PRIME H&amp;N Study)
Authors: L. Lorini, E. Stucchi, C. Gurizzan, C. Resteghini, D. Mattavelli, M. Ravanelli, C. Giannitto, A. Paderno, G. Mercante, G. Spriano, A. Alberti, S. Vecchio, A. Bozzola, C. Gottardi, M.G. Ghi, P. Nicolai, C. Dambrosio, M. Ferrari, P. Bossi
Journal: Annals of Oncology (2024)
576P Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: Results from a phase I study
Authors: J. Gong, C. Lemech, D. Day, J. Shan, M. Morris, A. Nagrial, M. Chen, X. Huang, H. Zong, N. Wang, Y. Yang, T. Yi, W. Li, Z. Zhuang, Z. Li, Z. Liu, Y. Luo, Y. Zhang, H. Zhou, L. Shen
Journal: Annals of Oncology (2024)
545P HIBRID: Histology and ct-DNA based risk-stratification with deep learning
Authors: C.M.L. Loeffler, S. Sainath, X. Jiang, Z. Carrero, M. van Treeck, T. Nishikawa, T. Misumi, Y. Nakamura, T. Yuan, D. Wankhede, M. Hoffmeister, H. Brenner, M. Liu, A. Jurdi, H. Bando, J.N. Kather, T. Yoshino
Journal: Annals of Oncology (2024)
341MO Impact of aging on the genetic and transcriptional landscape of advanced breast cancer: an AURORA program (BIG 14-01) subanalysis
Authors: G. Zoppoli, F. Ravera, F. Santaniello, L. Ferrando, D. Venet, J.A. Seoane, F. Richard, E. Munzone, S. Hatse, A. Ballestrero, T. Antoniolli Crestani, V.S. Adam, A. Irrthum, P.G. Aftimos, A.L. Guerrero Zotano, D.A. Cameron, M. Piccart, C. Desmedt, M. Benelli, H. Wildiers
Journal: Annals of Oncology (2024)
980P Hepatic artery infusion chemotherapy (HAIC) plus sintilimab and bevacizumab biosimilar (IBI305) for initial unresectable hepatocellular carcinoma (HCC) in patients with Child-Pugh B liver function: A prospective study
Authors: H. Li, X. Zhang, R. Li, Q. Qi, Y. Liu, L. Fu, X. Xie, Y. Liu
Journal: Annals of Oncology (2024)
569P Mismatch repair deficient, stage II/III rectal cancer: Real-world patient, tumour, and treatment characteristics in the Netherlands
Authors: R.A. Lunenberg, I.A. Franken, F.H. van der Baan, F.P.C. Sijtsma, G. Vink, M. Koopman, M. Intven, M.N.G.J.A. Braat, L. Moons, M. Laclé, M. Elferink, S.H. Boklage, J. Garside, R.V. Wuijtswinkel, J.M.L. Roodhart
Journal: Annals of Oncology (2024)
CN10 Stress of conscience in healthcare personnel caring for patients at the end of life during the COVID-19 pandemic
Authors: M. Larsson, C. Olsson, J. Appelgren, C. Bååth, M. Dahlen Granrud, V. Gröndahl, A.K. Helgesen, C. Melin Johansson, T. Sandsdalen, J. Österlind, M. Tillfors
Journal: Annals of Oncology (2024)
501TiP Clinical performance evaluation of a brain cancer liquid biopsy
Authors: J.M. Cameron, G. Antoniou, P. Brennan, H. Butler, D. Eustace, E. Gray, A. Jakola, M. Jenkinson, S. Koljenovic, A. Lazarus, R. Mathew, D. Palmer, I. Phang, A. Sala, T. Weiss, M.J. Baker
Journal: Annals of Oncology (2024)
CN57 Proposals for implementation of a multidimensional platform for the advancement of oncology nursing in Latin America (The INCREASE proposal)
Authors: J.A. Zuluaga, M. Parra, B. Prada, A. Casallas, L. Gutiérrez-Babativa, A. Jaramillo, L. Bernal, C. Klumpp, N. Sánchez, N. Wagner-Gutiérrez, A.F. Cardona Zorrilla
Journal: Annals of Oncology (2024)
804MO Gut microbiota composition is predictive of CAR-T cells response and its modulation enhances CAR-T cells activity
Authors: L. Marcos-Kovandzic, J. Rengassamy, G. Ferrere, J. Srikanthan, S. Durand, L. Derosa, C. Bigenwald, L. Zitvogel
Journal: Annals of Oncology (2024)
1065P Dose dependent detrimental effect of baseline pantoprazole on clinical outcomes from first-line chemo-ICI regimens in patients with advanced stage NSCLC
Authors: L. Brunetti, V. Santo, A. Palamara, G.R. Di Fazio, F. Citarella, A. Vendittelli, G. La Cava, E.C. Mingo, M. Fiorenti, F. Pantano, G. Tonini, B. Vincenzi, M. Russano, A. Cortellini
Journal: Annals of Oncology (2024)
1091P Neoadjuvant cemiplimab for stage II–IV cutaneous squamous cell carcinoma (CSCC): 2-year follow-up and biomarker analyses
Authors: D. Rischin, D.M. Miller, N.I. Khushalani, V. Divi, E. Ruiz, E.J. Lipson, F. Meier, Y.B. Su, P.L. Swiecicki, J. Atlas, J.L. Geiger, A. Hauschild, J.H. Choe, B.G.M. Hughes, S-Y. Yoo, L. Brennan, M.D. Mathias, H. Han, M.G. Fury, N. Gross
Journal: Annals of Oncology (2024)
941TiP A phase I/IIa, open-label, dose-finding trial to evaluate safety, immunogenicity, and anti-tumour activity of VB10.16 in combination with pembrolizumab in patients with unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (R/M HNSCC)
Authors: S. Khalique, M. Oliva, C. Even, R. Dziadziuszko, A. Dietz, A. Italiano, B. Melichar, J. Martinez-Galan, M. Brydøy, J. Thouvenin, T. Rutkowski, E. Hitre, M. Guix Arnau, M.P. Lopez Criado, T. Jürgens, Å. Bratland
Journal: Annals of Oncology (2024)
280P Personalized treatment approaches with HER2DX in early HER2-positive breast cancer: A precision tool for treatment decision-making
Authors: M. Tapia Céspedes, A. Llombart Cussac, C. Tebar, S.M. Liebana, A. Magro Molina, L. Palomar Abad, M.T.M. Martinez, C. Hernando Melia, V. Iranzo, A. Pouptsis, A. Santaballa Bertran, M.D. Torregrosa Maicas, O. Burgués, I. Garrido Cano, A. Lluch-Hernandez, P. Villagrasa Gonzalez, A. Prat, B. bermejo, J.M. Cejalvo
Journal: Annals of Oncology (2024)
293P Ultra-sensitive ctDNA detection and monitoring in early breast cancer using PhasED-Seq
Authors: L. Cabel, J. Ah-Reum An, D. Kurtz, D. Ross, E. Dikoglu, Y. Chen, K. Murphy, K. Szuhany, S. Love Stowell, D. Maloney, H.I. Scher, M. Morrow, M. Robson, S. Chandarlapaty, J. Chabon, A. Alizadeh, B.T. Li, G. Plitas, M. Diehn, P. Razavi
Journal: Annals of Oncology (2024)
539P Hepatic arterial infusion chemotherapy combined with sintilimab and regorafenib as adjuvant therapy for colorectal liver metastasis patients with high risk of recurrent: A single-arm, phase II study
Authors: L. Wang, T. Zhang, Y. Zhao, Y. Zhang, Z. Lin, Q. Pan, A. Mao, W. Zhu
Journal: Annals of Oncology (2024)
266P Association of RAD51 and efficacy outcomes in patients with HER2-negative breast cancer (BC) and homologous recombination deficiency (HRD): Post-hoc analysis of the GeparOla trial
Authors: G. Villacampa, N. Filmann, P.A. Fasching, J. Balmaña, T. Karn, F. Marmé, P. Klare, V. Mueller, C. Schem, T.N. Fehm, E. Stickeler, M. Van Mackelenbergh, B. Felder, V. Nekljudova, A. Llop-Guevara, C. Denkert, S. Loibl, V. Serra
Journal: Annals of Oncology (2024)
250P Development and validation of a 19-feature classifier that predicts response to neoadjuvant trastuzumab emtansine (T-DM1) in breast cancer patients
Authors: F. Pareja, E.D. Paul, B. Huraiová, N. Valková, N. Matyašovská, D. Gábrišová, S. Gubová, H. Ignačáková, T. Ondris, S. Bendíková, D. Lovíšek, M. Gala, I. Comino-Mendez, J.N. Kather, P. Cekan
Journal: Annals of Oncology (2024)
264P Neuropsychological and morphological effects of simultaneous exercise during neo-/adjuvant chemotherapy in breast cancer patients: The Exercise Cancer and Cognition (ECCO) study
Authors: D. Kiesl, F. Purgar, M. Kuzdas-Sallaberger, S. Brunner, C. Tischler, A. Reichinger, N. Klambauer, M. Vosko, P. Zimmer
Journal: Annals of Oncology (2024)
260P Impact of HER2-low status on clinicopathological characteristics and pathological complete response in luminal and triple-negative early breast cancer
Authors: K. Pogoda, M. Czopowicz, A. Bak, P. Halasa, D. Najmrocka, H. Pawlik, W. Olszewski, M. Rosinska, A. Niwinska, E. Sarnowska, E. Szombara, I. Lemanska, R. Sienkiewicz, E. Brewczynska, A. Konieczna, A. Balata, A. Majstrak-Hulewska, Z. Nowecki
Journal: Annals of Oncology (2024)
261P Subtyping of residual disease (RD) following neoadjuvant chemotherapy (NACT) for triple negative breast cancer (TNBC): Evolution and prognostic impact
Authors: I. Echavarria Diaz-Guardamino, S. Lopez-Tarruella Cobo, M. Del Monte-Millan, E. Alvarez, Y. Jerez Gilarranz, F. Moreno Anton, J.Á. García Saenz, T. Massarrah, I. Ocaña, M. Cebollero, A.I. Ballesteros Garcia, U. Bohn Sarmiento, H. Gomez, H. Fuentes Rivera, B. Herrero Lopez, C. Polo, O. Bueno, P. Rahimi, C. Bueno Muiño, M. Martin Jimenez
Journal: Annals of Oncology (2024)
815MO A prospective study of orelabrutinib plus obinutuzumab (O2) in treatment-naïve marginal zone lymphoma (MZL): Preliminary analysis on efficacy and safety
Authors: J-D. Xu, L-Y. Cheng, J. Li, J-L. Zhuang, Z-X. Cheng, Y-H. Ren, Y-A. Zhang, Y. Wang, P. Liu
Journal: Annals of Oncology (2024)
CN8 Revolutionizing oncological care: Successful implementation of home-based antineoplastic treatments
Authors: M. Lanza Postigo, B. Gómez-Mediavilla, F. Rivera Herrero, C. Hinojo González, D. Cacho Lavin, E. Martinez de Castro, I. Gardeazabal Gonzalez, C. Valencia Soto, A. Garcia-Avello Fernández-Cueto
Journal: Annals of Oncology (2024)
303P Predicting quality of life trajectories in young women with breast cancer: 5-year results from a large prospective cohort
Authors: B.F. Vaca-Cartagena, A.S. Ferrigno Guajardo, H.A. Azim, F. Rotolo, A. Olivas-Martinez, A. Platas, A. Fonseca, F. Mesa-Chavez, M. Cruz Ramos, A. Rodríguez, A. Mohar, C. Villarreal-Garza
Journal: Annals of Oncology (2024)
547P Artificial Intelligence-powered analysis of the tumor immune microenvironment in primary and metastatic colorectal cancer
Authors: E. Adib, F. Jabar, M. Tafavvoghi, E.B. Farhat, A. Nassar, L-T.R. Busund, T. Donnem, A. Helland, D.J. Kwiatkowski, M. Rakaee
Journal: Annals of Oncology (2024)
276P SHR-A1811 in combination with pyrotinib as neoadjuvant treatment for HER2-positive breast cancer (HER2+ BC): Preliminary results from MUKDEN 07
Authors: C.G. Liu, N. Niu, F. Qiu, X. Gu, X. Zheng, J. Guo, X. Bian, J. Xue, G. Chen, S. Han, Y. Xu, Y. Zhao, F. Xing, J. Yin, G. Song, Y. Wang, M. Tang, Y. Song, J. Wang
Journal: Annals of Oncology (2024)
237MO TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy without immunotherapy
Authors: M. Martin Jimenez, O. Gluz, G. Villacampa, S. Lopez-Tarruella Cobo, U.A. Nitz, S. Cobo, F. Brasó-Maristany, M. Christgen, Y. Jerez Gilarranz, S. Kummel, B. Conte, I. Echavarria Diaz-Guardamino, M.K. Graeser-Mayer, H. Kreipe, M. Del Monte-Millan, B. Herrero Lopez, C.M. Perou, L. Pare Brunet, A. Prat, N. Harbeck
Journal: Annals of Oncology (2024)
302P Perceptions of women with HER2+ breast cancer on the risk of recurrence and disease management: Results from the ASKHER survey
Authors: M. Lambertini, O. Tredan, M.J. Vidal Losada, M. Fontes e Sousa, A. Valachis, R. D’Antona Fidanzia, M. Ruz, E. Krone, M. Brice, E. Berjonneau, S. Matos, O. Dialla, C. Jackisch
Journal: Annals of Oncology (2024)